Impact of risperidone long-acting injectable on hospitalisation and medication use in Canadian patients with schizophrenia

Journal of Medical Economics

Volumn 10, Issue 4, 2007, Pages 427-442

  Beauclair, Linda ^a,f   Chue, Pierre ^b   McCormick, John ^c   Camacho, Fernando ^d   Lam, Annette ^e   Luong, Doanh ^e  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c McKesson Canada   (Canada)

^d DAMOS Inc   (Canada)

^e Janssen Ortho Inc   (Canada)

^f Allan Memorial Institute   (Canada)

Author keywords

Medication switching; Oral atypical; Risperidone long acting injectable; Schizophrenia related hospitalisation

Indexed keywords

ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEDATIVE AGENT;

ADULT; AGED; ARTICLE; CANADA; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; RISK REDUCTION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; UNSPECIFIED SIDE EFFECT;

EID: 38149088752     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990701646825     Document Type: Article

References (41)

1. Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics. Part 1: pharmacology, pharmacokinetics, and efficacy Annals of Pharmacotherapy 1999; 33: 73-85.
2. Leucht S, Barnes TR, Kissling W et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. American Journal of Psychiatry 2003; 160: 1209-1222.
3. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. Canadian Medical Association Journal 2005; 172: 1703-1711.
4. Dolder CR, Lacro JP, Dunn LB et al. Antipsychotic medication adherence: is there a difference between typical and atypical agents? American Journal of Psychiatry 2002; 159: 103-108.
5. Kane JM, Eerdekens M, Lindenmayer J-P et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. American Journal of Psychiatry 2003; 160: 1125-1132.
6. Knapp M, King D, Pugner K et al. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. British Journal of Psychiatry 2004; 184: 509-516.
7. Valenstein M, Blow FC, Copeland LA et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophrenia Bulletin 2004; 30: 255-264.
8. Young JL, Zonana HV, Shepler L. Medication noncompliance in schizophrenia: codification and update. Bulletin of the American Academy of Psychiatry and the Law 1986; 14: 105-122.
9. Valenstein M, Copeland LA, Blow FC et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Medical Care 2002; 40: 630-639.
10. Goeree R, Farahati F, Burke N et al. The economic burden of schizophrenia in Canada in 2004. Current Medical Research and Opinion 2005; 21: 2017-2028.
11. Bhanji NH, Chouinard G, Margolese HC. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. European Neuropsychopharmacology 2004; 14: 87-92.
12. Adams CE, Fenton MK, Quraishi S et al. Systematic meta-analysis of depot antipsychotic drugs for people with schizophrenia. British Journal of Psychiatry 2001; 179: 290-299.
13. Davis JM, Matalon L, Watanabe MD et al. Depot antipsychotic drugs: place in therapy. Drugs 1994; 47: 741-773.
14. Chue P, Llorca P-M, Duchesne I et al. Hospitalization rates in patients during long-term treatment with long-acting risperidone injection. Journal of Applied Research 2005; 5: 266-274.
15. Altamura AC, Sassella F, Santini A et al. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Drugs 2003; 63: 493-512.
16. Kelleher JP, Centorrino F, Albert MJ et al. Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents. CNS Drugs 2002; 16: 249-261.
17. Fleischhacker WW, Eerdekens M, Karcher K et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. Journal of Clinical Psychiatry 2003; 64: 1250-1257.
18. Lasser RA, Bossie CA, Gharabawi GM et al. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. European Psychiatry 2004; 19: 219-225.
19. Lasser RA, Bossie CA, Gharabawi GM et al. Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial. International Journal of Neuropsychopharmacology 2005; 8: 427-438.
20. Turner M, Eerdekens E, Jacko M et al. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. International Clinical Psychopharmacology 2004; 19: 241-249.
21. Lasser RA, Bossie CA, Gharabawi GM et al. Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophrenia Research 2005; 77: 215-227.
22. Eriksson L, Almqvist A, Mehnert A et al. The use of institutional psychiatric care significantly decreases with long-acting risperidone. In: 45th Annual and 4th Mediterranean Meeting of the Scandinavian College of Neuro-Psychopharmacology; 21-24 April 2004; Juan-les-Pins, France.
23. Leal A, Rosillon D, Mehnert A et al. Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone. Pharmacoepidemiology and Drug Safety 2004; 13: 811-826.
24. Addington DE, Jones B, Bloom D et al. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clinical Therapeutics 1993; 15: 917-926.
25. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: APA, 1994.
26. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 1958; 53: 457-481.
27. Lawless JF. Statistical Models and Methods for Lifetime Data. New York, NY: John Wiley & Sons, 1982.
28. Cox DR. Regression models and life-tables. Journal of the Royal Statistical Society Series B (Statistical Methodology) 1972; 34: 187-220.
29. McNemar Q. Note on the sampling error of the difference between correlated proportions of percentages. Psychometrika 1947; 12: 153-157.
30. Davies LM, Drummond MF. Economics and schizophrenia: the real cost. British Journal of Psychiatry Supplement 1994; 25: 18-21.
31. Conley RR, Love RC, Kelly DL et al. Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. American Journal of Psychiatry 1999; 156: 863-868.
32. Niaz OS, Haddad PM. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatrica Scandinavica 2007; 116: 36-46.
33. Genduso LA, Haley JC. Cost of illness studies for schizophrenia: components, benefits, results and implications. American Journal of Managed Care 1997; 3: 873-877.
34. Paton C, Okocha C. Risperidone long-acting injection: the first 50 patients. Psychiatric Bulletin 2004; 28: 12-14.
35. Young CL, Taylor DM. Health resource utilization associated with switching to risperidone long-acting injection. Acta Psychiatrica Scandinavica 2006; 114: 14-20.
36. Taylor D. Risperidone long-acting injection in practice - more questions than answers? Acta Psychiatrica Scandinavica 2006; 114: 1-2.
37. Lieberman JA, Scott StroupT, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with schizophrenia. New England Journal of Medicine 2005; 353: 1209-1223.
38. Edwards NC, Rupnow MFT, Pashos CL et al. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US. PharmacoEconomics 2005; 23: 299-314.
39. Ontario Case Costing Initiative. Available at: http://www.occp.com/ [last accessed 24 August 2007].
40. Foster RH, Goa KL. Risperidone. A pharmacoeconomic review of its use in schizophrenia. PharmacoEconomics 1998; 14: 97-133.
41. Chue PS, Heeg BMS, Buskens E et al. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. PharmacoEconomics 2005; 23(Suppl. 1): 62-74.